# Cardioprotective Empagliflozin for Cancer Patients Receiving Doxorubicin

> **NCT06103279** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Ain Shams University** · enrollment: 40 (estimated)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** Empagliflozin 10 MG

## Key facts

- **NCT ID:** NCT06103279
- **Lead sponsor:** Ain Shams University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-11
- **Primary completion:** 2024-07
- **Final completion:** 2024-08
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2023-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06103279

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06103279, "Cardioprotective Empagliflozin for Cancer Patients Receiving Doxorubicin". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06103279. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*